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facing a true epidemic of glomerular 
sclerosis, dissecting its pathogenesis, one 
pathway at a time, is a welcome step. We 
cannot devise effective therapies for 
glomerular sclerosis unless we know its 
pathomechanism. We need to identify 
and learn how to control the responsible 
receptors triggering the pathways to 
sclerosis. 
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 Vitamin D supplementation after 
renal transplantation: how much 
vitamin D should we prescribe ? 
 Ronen  Levi 1 and  Justin  Silver 1 
 Vitamin D deficiency is common in patients with chronic kidney disease 
after renal transplantation. Vitamin D, essential for mineral and bone 
metabolism, also has myriad beneficial autocrine effects on intact 
immune responses and defense against infection, as well as suppression 
of malignant changes. Supplementation with oral parental vitamin D 
could correct this problem. Courbebaisse  et al. define how much oral 
vitamin D to prescribe to renal allograft recipients. 
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keratinocytes? Vitamin D is critically impor-
tant for the development, growth, and main-
tenance of a healthy skeleton from birth until 
death. ' e major function of vitamin D is to 
maintain calcium homeostasis. It accom-
plishes this by increasing the e3  ciency with 
which the intestine absorbs dietary calcium. 
When there is inadequate calcium in the diet 
to satisfy the body ’ s calcium requirement, 
vitamin D and other humoral and local fac-
tors communicate to the osteoblasts that 
then signal osteoclast precursors to mature 
and dissolve the calcium stored in the bone. 2 
Vitamin D 3 is metabolized in the liver to 
produce 25-hydroxyvitamin D 3 (25(OH)D) 
and then in the kidney to 1,25-dihydroxyvi-
tamin D 3 (1,25(OH) 2 D), the biologically 
active form of the vitamin. 1,25(OH) 2 D acts 
on its receptors, the vitamin D receptors, 
which are present not only in the intestine 
and bone, but in a wide variety of other tis-
sues, including the brain, heart, stomach, 
pancreas, activated T and B lymphocytes, 
skin, and gonads. Muscle function, innate 
immunity, cellular growth and maturation, 
immunomodulation, and insulin secretion, 
as well as the regulation of calcium, phos-
phorus, and bone meta bolism, are all a8 ected 
or controlled by vitamin D ( Figure 1 ). 
1,25(OH) 2 D is one of the most potent sub-
stances to inhibit proliferation of both nor-
mal and hyperproliferative cells and induce 
them to mature. It is also recognized that 
apart from the 1,25(OH) 2 D synthesized and 
 Vitamin D is an ancient hormone identi ed 
in the ocean-driG ing organisms, the plank-
ton that evolved over 750 million years ago. 
Without plankton there would be no life, 
and phytoplankton have the essential capac-
ity not only to recycle carbon but also to 
synthesize vitamin D. The ingestion of 
plankton in the depths of the oceans pro-
vides the vitamin D content of fish, and 
hence a plentiful supply for fish-eating 
humans. In the cauldrons of time  Homo 
sapiens evolved half a billion years later, 
developed remarkable cognitive neurodevel-
opment, and retained the ability to e3  ciently 
synthesize vitamin D 3 or cholecalciferol 
when exposed to the ultraviolet B rays of 
sunlight. However, we are constrained by a 
limited opportunity to bare our bodies to the 
joys of the sun, clouded by a concern for the 
harmful e8 ects of excess ultraviolet B rays. 
Transplant patients are well advised to limit 
their exposure to the ultraviolet B rays and 
their potentially damaging e8 ects because a 
well-documented complication of immuno-
suppressive therapy is the far greater inci-
dence of skin cancers. 1 But what about the 
bene cial e8 ects of ultraviolet B in initiating 
the photosynthesis of cholecalciferol in their 
see original article on page 646
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secreted by the kidney, a wide variety of tis-
sues, including parathyroid, colon, prostate, 
breast, and skin, have the enzymatic machin-
ery to produce 1,25(OH) 2 D, which then has 
a local autocrine or paracrine action rather 
than a systemic hormonal action. 2 
 ' e regulation of mineral metabolism in 
physiology and disease has taken great 
strides recently with the elucidation of the 
sequences of events in the development of 
the changes in mineral and bone disease in 
chronic kidney disease (CKD). Speci cally, 
it is now apparent that  broblast growth fac-
tor-23 (FGF23), secreted by osteocytes, is 
increased in CKD, in part by the stimulus of 
the phosphate retention of CKD. 3 The 
increased levels of FGF23 then act on its 
receptor, Klotho-FGFR1c, in the kidney and 
the parathyroid. 4,5 In the kidney, it decreases 
the synthesis of 1,25(OH) 2 D and leads to 
phosphaturia, and in the parathyroid, it 
decreases parathyroid hormone (PTH) gene 
expression and PTH secretion. 5 Despite the 
decreased serum 1,25(OH) 2 D levels in 
patients with CKD, due to a direct inhibi-
tory e8 ect of a raised serum phosphate as 
well as FGF23 action, we should not be sat-
is ed with just prescribing 1,25(OH) 2 D or 
its analogues. We must also ensure that our 
patients have adequate levels of 25(OH)D, 
which reJ ects their nutritional vitamin D 
status and provides a substrate for the local 
synthesis of 1,25(OH) 2 D, which may then 
exert its myriad local autocrine effects, 
which are all bene cial to health. Vitamin 
D de ciency is a major unrecognized health 
problem. Not only does it cause rickets in 
children, and osteomalacia in adults, but it 
may have long-lasting e8 ects on other organ 
systems. 
 Epidemiological evidence has been accru-
ing for the past 40 years that low vitamin D 
levels are associated with a large number of 
diverse diseases. ' ese include cancer of the 
breast, prostate, and colon as well as diabe-
tes mellitus and tuberculosis. 2 Recent exper-
imental studies have been astoundingly 
refreshing and insightful in shedding light 
on the mechanisms involved. ' ere is thus 
every reason to ensure that the patients we 
treat and all our fellow citizens are in a vita-
min D-replete state. It has been di3  cult to 
de ne vitamin D repletion. 6 To wait for the 
consequences of a low serum calcium lead-
ing to secondary hyperparathyroidism with 
correction of the serum calcium at the 
expense of bone and the trade-o8  of phos-
phaturia is to miss the boat and expose 
people unnecessarily to the complications of 
vitamin D insu3  ciency. We now have target 
levels of 25(OH)D, which we should aspire 
to reach, but even these levels may be set too 
low. You will be surprised how many around 
you, including yourselves, family, and col-
leagues, do not reach these levels. ' ey are 
serum 25(OH)D of greater than 30  ng / ml. 
Less than 30  ng / ml but greater than 15  ng / ml 
is vitamin D insu3  ciency and exposure to 
all the ills of too little vitamin D. Less than 
15  ng / ml is vitamin D de ciency, which is 
dangerous. Patients with CKD have long 
been known to su8 er from vitamin D de -
ciency, which is an integral component in 
the pathogenesis of renal bone disease. 7 A 
recent analysis of data from the Third 
National Health and Nutrition Examination 
Survey showed that in a large sample of 
more than 15,000 study participants, 
25(OH)D levels less than 30  ng / ml are much 
more prevalent in CKD patients than in the 
general population, a8 ecting nearly a third 
of the participants, and this was not related 
to di8 erences in dietary intake. 8 How much 
vitamin D to prescribe? Well, we really have 
been pretty much in the dark. So the article 
by Courbebaisse  et al. 9 in this issue of  Kidney 

















 Figure 1 |  Metabolic, endocrine, and autocrine action of vitamin D. FGF23, fibroblast growth factor-23. 
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 Courbebaisse  et al . 9 compared outcomes 
in patients with 25(OH)D concentration 
less than 30  ng / ml and normal serum cal-
cium, treated or not treated with cholecal-
ciferol. ' ey showed that treating patients 
with 100,000 units of cholecalciferol every 
2 weeks for 2 months may be enough to 
significantly elevate serum levels of 
25(OH)D to above 30  ng / ml and reduce 
PTH levels without consequent hypercal-
cemia or increased urinary calcium excre-
tion, which could adversely a8 ect graG  
function. However, during the less inten-
sive phase of the treatment, when chole-
calciferol was given at the same dose every 
other month, serum levels of 25(OH)D 
decreased again, though they remained 
higher than in control untreated patients 
at 1 year aG er transplantation. ' e message 
to be drawn from this study is that we need 
to prescribe large doses of cholecalciferol 
for our patients aG er renal transplantation. 
In addition, we need similar bold studies 
on the correct dose of cholecalciferol or 
ergocalciferol to prescribe for our patients 
at the di8 erent stages of CKD. 10 
 Current Kidney Disease Outcomes Qual-
ity Initiative guidelines de ne de ciency of 
vitamin D metabolites as less than 15  ng / ml 
for 25(OH)D 3 , but this does not account for 
the other consequences of vitamin D insuf-
ficiency. The first parameter of mineral 
metabolism to be decreased in patients with 
early CKD was shown by Levin  et al. 11  to be 
serum 1,25(OH) 2 D. ' at is an important 
observation, and it would be of great interest 
to test the response of those patients with 
early CKD to oral vitamin D rather than oral 
1,25(OH) 2 D or its analogues. 
 Until then, it is incumbent upon us to 
increase the dose and maintain levels of 
25(OH)D in all our patients and in the gen-
eral population where we may have some 
small inJ uence. We need to rise to the chal-
lenge and make broad public appeals for 
wider supplementation with vitamin D and 
a prudent exposure to sunlight. 
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have no tubular secretion or reabsorp-
tion, and have no extrarenal clearance. In 
order to interpret levels of any proposed 
marker used in estimation of GFR, it is 
important to understand the factors that 
alter the generation, elimination, and 
analysis. ' e factors associated with cre-
atinine are well understood, but this is 
not the case with cystatin C. Cystatin C is 
a 120-amino acid cysteine protease inhib-
itor. It is produced and secreted by all 
nuclear cells. 1 It functions extracellularly 
to inhibit papain-like cysteine protease 
inhibitors. 2 It is freely filtered at the 
glomerulus, reabsorbed by proximal 
tubules via megalin-mediated endocyto-
sis, and catabolized. 3 
 Stevens  et al. 4 (this issue) analyzed 
the associations with cystatin C and 
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 Measuring glomerular filtration rate 
(GFR) in every patient is not practical in 
clinical care or large epidemiologic stud-
ies. ' is leaves us with estimation of GFR 
using endogenous markers, such as cre-
atinine and cystatin C. ' e ideal endog-
enous marker does not exist. An ideal 
marker would have a constant generation 
rate, be freely  ltered at the glomerulus, 
 Creatinine and cystatin C: 
what are the values? 
 Linda F. Fried 1 , 2 , 3 
 Recent studies indicate that serum cystatin C is a better marker of 
glomerular filtration rate (GFR) and is a stronger predictor of cardiovascular 
disease and mortality than serum creatinine. Before cystatin C can gain 
wide acceptance, information about factors that affect generation, 
elimination, and analysis is needed. Stevens  et al. analyze non-GFR – related 
factors associated with cystatin C and creatinine levels. The results will be 
useful in interpreting cystatin C levels in research and clinical practice. 
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